From Earlier: Merck ISENTRESS in Combination Therapy Demonstrated Long-Term Efficacy, Safety and Tolerability in Previously Untreated Adult Patients with HIV-1 for up to 240 Weeks

Eddie Staley, Benzinga Staff Writer

July 23, 2012 6:10 AM

+ Follow

Print

Email

Tickers: MRK

Benzinga Share:

Get News First. Profit Faster

With Benzinga Professional get unlimited access to ALL content! PLUS:

• REALTIME NEWSFEED
• REALTIME AUDIO NEWS
• FULL CALENDAR SUITE
• CHAT WITH OUR NEWS DESK

RECENT PRO ALERTS

• Citigroup Awards Pandit $6.65M Incentive Award

  05:14pm - November 9, 2012

• S&P Cuts JC Penney to B- from B+

  04:51pm - November 9, 2012

• Netflix Rises 3% After-Hours

  04:49pm - November 9, 2012

Posted in: News, FDA

Advertisement

 

Advertisement

Around the Web, We're Loving...

Chinese react favorably to Obama win

Boehner: Obamacare is 'Law of the Land'

Global Shares Slide Amid Fiscal Cliff, EU Worries

Something All Investors Must Do During Earnings Season

Priceline-Kayak Deal Shakes Up Online Travel Market

QE Fatigue Becomes an Epidemic

Most Popular

The Week Ahead: Home Depot, Dell, Walmart Earnings; European GDP

Disney Loses 6% After Q4 Results; Stock at 4 Month Low

Kayak's Acquisition Shows IPOs Can be Profitable

Benzinga's M&A Chatter for Friday November 9, 2012

Mid-Afternoon Market Update: Markets Slow Their Rally; Groupon Trades Down on Massive Volume

Utilities ETF Failed Conservative Investors This Week

Related Articles (MRK)

Futures Flat, Euro Falls Ahead of Central Banks

Moves in Smaller Health Care Stocks (GMED, SEM, UAM, VRTX)

More Equal-Weight ETFs Your Broker Forgot to Mention

UPDATE: BMO Capital Markets Reiterates Market Perform Rating, Raises PT on Merck & Co.

S&P Bullish on Select Dividend ETFs

Benzinga Market Primer, Friday, October 26

Partner Network